Clinical Trial

EXoPERT EMERALD Clinical Study

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-08-31 2026-07-02
minor Completion pushed: 2026-06-30 -> 2026-08-31 2026-07-02
Trial Details
NCT Number NCT07186296
Lead Sponsor EXoPERT
Collaborators: MCRA
Conditions Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
Enrollment 1,400 participants
Start Date 2025-05-09
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01